RVBA-PFIZEPharma Manufacturing

Pfizer — in detail

Full extracted data, every event in the company's history we've captured, and (soon) external news. The full ratios diagnostic with peer benchmarks lives at /ratios.

Reference sources (3/5)

Source documents
Recent disclosure
Multi-year metrics
Targets
Certifications

External news

No ESG-relevant news ingested yet for this company. Run python -m pipeline.news_gdelt to backfill. Sourced from GDELT 2.0 (3-month trailing window).

Data by year· every metric + key events per year

Each year shows the firm's reported metrics on the left and the most material events on the right. Up to 10 events per year; the full event log is one click further.

2025

cdp response ↗

P&L highlights (USD)

Headcount (FTE)	75,000people
Revenue	62.6B
Cost of revenue	(18.6B)
Gross profit	44B
Operating expenses (S&M + G&A)	(28.6B)
Operating income	15.4B
Net income	7.8B

Balance sheet highlights (USD)

Property, plant & equipment	21.5B
Total assets	208.2B
Total debt	65.1B
Cash & equivalents	1.1B
Minority interest	299M

Market & shares

Market cap (FY-end)	141.5B
Shares outstanding	5.7B

2024

Climate · carbon footprint (tCO2e)

Scope 1	613,218
Scope 2 (market-based)	465,128
Scope 3	3.6M
Cat 1 · Purchased goods	2.8M
Cat 6 · Business travel	188,309
Cat 7 · Employee commuting	20,564
Cat 8 · Upstream leased	15,511
Cat 15 · Investments	7,342
Gross carbon footprint	4.6M
Net carbon footprint	4.6M

Energy (kWh)

Renewable energy %

14%

P&L highlights (USD)

Headcount (FTE)	81,000people
Revenue	63.6B
Cost of revenue	(21.8B)
Gross profit	41.8B
Operating expenses (S&M + G&A)	(25.4B)
Operating income	16.5B
Net income	8B

Balance sheet highlights (USD)

Property, plant & equipment	18.4B
Total assets	213.4B
Total debt	64.4B
Cash & equivalents	1B
Minority interest	294M

Market & shares

Market cap (FY-end)	150.3B
Shares outstanding	5.7B

Events 2024· 7

2019 base year emissions recalculated (Scope 1, 2, 3)

Base year (2019) emissions recalculated for Scope 1, Scope 2 location and market-based, and Scope 3 due to methodology changes and structural changes (Seagen acquisition, Karachi divestiture). Limited assurance obtained for updated 2019 baseline covering Scope 1, 2, and Scope 3 categories 1, 2, 4, 5, 6.

▾ expand

VPPAs covering ~100% of NA and EU electricity coming online in 2025

VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU.

▾ expand

Reasonable assurance obtained for Scope 1 and Scope 2 emissions

Pfizer obtained reasonable assurance (ISAE 3000) for Scope 1 and Scope 2 (location and market-based) emissions, with limited assurance for Scope 3 categories. This represents a higher level of assurance than typical limited assurance.

▾ expand

Sold Karachi, Pakistan manufacturing site to Lucky Core Industries

Pfizer's manufacturing site in Karachi, Pakistan was sold to Lucky Core Industries (LCI) in 2024. Also exited former NY HQ in July 2024 following lease expiry.

▾ expand

Added well-to-wheel emissions to air travel (Scope 3 Cat 6)

Air travel emissions for 2023 were adjusted to include well-to-wheel (WTW) emissions in accordance with the GHG Protocol, resulting in an 8% increase from the previously reported value for Business Travel. This makes the inventory more complete.

▾ expand

Refined upstream transportation methodology (logistics & tertiary packaging weights)

Historical upstream transportation and distribution emissions for 2023 recalculated due to methodology improvements accounting for logistics and tertiary packaging material weights, resulting in a 16% decrease from previously reported value.

▾ expand

Reclassified 3 remediation sites from Scope 1+2 to Scope 3 Cat 1

Three remediation sites previously classified under Pfizer's operational control have been reclassified as Scope 3, Category 1: Purchased Goods and Services, reflecting their management by third parties under service contracts.

▾ expand

2023

cdp response ↗

Climate · carbon footprint (tCO2e)

Scope 1	617,404
Scope 2 (market-based)	490,632
Scope 3	4.3M
Cat 1 · Purchased goods	3.4M
Cat 6 · Business travel	186,396
Cat 7 · Employee commuting	21,745
Cat 8 · Upstream leased	26,497
Cat 15 · Investments	6,754
Gross carbon footprint	5.4M
Net carbon footprint	5.4M

P&L highlights (USD)

Headcount (FTE)	88,000people
Revenue	59.6B
Cost of revenue	(29.2B)
Gross profit	30.3B
Operating expenses (S&M + G&A)	(25B)
Operating income	5.3B
Net income	2.1B

Balance sheet highlights (USD)

Property, plant & equipment	18.9B
Total assets	226.5B
Total debt	70.8B
Cash & equivalents	2.9B
Minority interest	274M

Market & shares

Market cap (FY-end)	162.5B
Shares outstanding	5.6B

2022

Climate · carbon footprint (tCO2e)

Scope 1	650,587
Scope 2 (market-based)	475,107
Cat 1 · Purchased goods	8.2M
Cat 6 · Business travel	80,167
Cat 7 · Employee commuting	38,557
Cat 8 · Upstream leased	30,449
Cat 15 · Investments	6,939
Gross carbon footprint	—
Net carbon footprint	—

Energy (kWh)

Renewable energy %

P&L highlights (USD)

Headcount (FTE)	83,000people
Revenue	100.3B
Cost of revenue	(38.2B)
Gross profit	62.1B
Operating expenses (S&M + G&A)	(24.5B)
Operating income	37.5B
Net income	31.4B

Balance sheet highlights (USD)

Property, plant & equipment	16.3B
Total assets	197.2B
Total debt	34.9B
Cash & equivalents	416M
Minority interest	256M

Market & shares

Market cap (FY-end)	287.4B
Shares outstanding	5.6B

Events 2022· 8

Net-Zero by 2040 commitment announced (10 years ahead of standard)

In June 2022, Pfizer's CEO committed to achieving the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard. Aims to decrease company GHG emissions by 95% and value chain emissions by 90% from 2019 levels.

▾ expand

Acquired Arena Pharmaceuticals and Global Blood Therapeutics R&D facilities

Acquired ~125,000 sq ft leased R&D laboratory in San Diego from Arena Pharmaceuticals (March 2022) and ~164,000 sq ft leased R&D site in San Francisco from Global Blood Therapeutics (October 2022). Added approximately 2,380 mt CO2e to Scope 1+2.

▾ expand

Pfizer commits to SBTi Net-Zero by 2040

In June 2022, the CEO committed to accelerating the decarbonization of Pfizer's value chain, aiming to achieve SBTi's voluntary Net-Zero Standard by 2040, including a 90% absolute reduction in value chain emissions by 2040 from a 2019 baseline.

▾ expand

Expanded Scope 3 business travel boundary to include US Fleet personal vehicle use

Pfizer expanded its boundary for Scope 3 Business Travel to include use of personal vehicles for business by US Fleet colleagues. Baseline (2019) and 2019-2022 calculations were updated to reflect this.

▾ expand

Revised Scope 3 Upstream Transportation & Distribution methodology

Pfizer revised its methodology for calculating emissions for Scope 3 Upstream Transportation & Distribution to more accurately capture source data and applied this methodology to 2019-2022 calculations.

▾ expand

Baseline adjusted for acquisitions, divestitures and closures

Pfizer's reporting boundary was baseline-adjusted per the GHG Protocol to reflect acquisitions (Arena Pharma San Diego R&D, Global Blood Therapeutics San Francisco R&D), divestitures (Adelaide Australia, Valencia Venezuela manufacturing sites) and closures.

▾ expand

Divested Haleon joint venture

In June 2022, Pfizer announced plans to exit ownership interest in Haleon (former GSK joint venture). Emissions from this entity are no longer included in Scope 3 Cat 15 Investments, contributing to lower investments emissions vs base year.

▾ expand

Reasonable assurance for Scope 1, 2 and Scope 3 categories 1, 3, 4, 6

Scope 1 and Scope 2 emissions verified to reasonable assurance level (ISAE3000) by ERM CVS. Scope 3 verified to limited assurance.

▾ expand

2021

Climate · carbon footprint (tCO2e)

Scope 1	661,930
Scope 2 (market-based)	484,316
Gross carbon footprint	—
Net carbon footprint	—

P&L highlights (USD)

Headcount (FTE)	79,000people
Revenue	81.3B
Cost of revenue	(34.4B)
Gross profit	46.9B
Operating expenses (S&M + G&A)	(26.1B)
Operating income	20.8B
Net income	22.1B

Balance sheet highlights (USD)

Property, plant & equipment	14.9B
Total assets	181.5B
Total debt	37B
Cash & equivalents	1.9B
Minority interest	262M

Market & shares

Market cap (FY-end)	330.7B
Shares outstanding	5.6B

2020

Climate · carbon footprint (tCO2e)

Scope 1	649,357
Scope 2 (market-based)	509,420
Gross carbon footprint	—
Net carbon footprint	—

P&L highlights (USD)

Headcount (FTE)	78,500people
Revenue	41.7B
Cost of revenue	(11.8B)
Gross profit	29.9B
Operating expenses (S&M + G&A)	(20.8B)
Operating income	9.1B
Net income	9.2B

Balance sheet highlights (USD)

Property, plant & equipment	13.7B
Total assets	154.2B
Total debt	38.3B
Cash & equivalents	1.8B
Minority interest	235M

Market & shares

Market cap (FY-end)	204.5B
Shares outstanding	5.6B

Events 2020· 3

Supplier engagement target: 64% of suppliers by spend with SBT by 2025

Pfizer committed to engage at least 64% of suppliers by spend to adopt science-based GHG reduction targets by 2025. At end of 2022, 29% of suppliers by spend had committed to or set SBTi targets.

▾ expand

SBTi-validated near-term targets (Scope 1+2 -46% by 2030, Scope 3 cat 4 -10% by 2025, business travel -25% by 2025)

Set in 2020 and approved by SBTi: 46% absolute reduction in Scope 1+2 by 2030 from 2019 baseline (1.5°C aligned); 10% reduction in Scope 3 upstream transport by 2025; 25% reduction in business travel by 2025; 100% renewable electricity by 2030.

▾ expand

SBTi-validated near-term targets set: 46% Scope 1+2 reduction by 2030

Pfizer set science-based targets validated by SBTi for 46% reduction in Scope 1+2 emissions by 2030 vs 2019 baseline (1.5°C aligned), 25% reduction in business travel by 2025, 10% reduction in upstream transportation by 2025, and 64% of suppliers by spend with science-based targets by 2025.

▾ expand